Case Report
Accepted on 13 Feb 2026
Exceptional Response to Furmonertinib in Lung Adenocarcinoma Harboring HER2 Exon 20 Insertion Mutation: A Case Report
in Thoracic Oncology
Frontiers in Oncology
- Frontiers in Oncology
- Thoracic Oncology
- Articles
Type at least 3 characters
1,969 articles
articles
Case Report
Accepted on 13 Feb 2026
Intraoperative Vascular Ligation Uncovers the Role of Tumor Vasculature in Doege-Potter Syndrome: A Case Report
in Thoracic Oncology
Frontiers in Oncology
Systematic Review
Published on 13 Feb 2026
Comparative efficacy of trastuzumab deruxtecan versus guideline-recommended treatments for 2L+ unresectable locally advanced or metastatic HER2-mutant non-small cell lung cancer: a systematic review and indirect treatment comparison
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2025.1708245
- 428 views
Case Report
Accepted on 12 Feb 2026
Complete Remission of Thymic Carcinoma Using Dose-Dense Chemotherapy
in Thoracic Oncology
Frontiers in Oncology
Case Report
Accepted on 12 Feb 2026
Case Report: Pregnant ROS1+ Lung Cancer Patient Treated with Crizotinib: Impact on Infancy
in Thoracic Oncology
Frontiers in Oncology
Case Report
Accepted on 12 Feb 2026
Acquired EGFR L858R mutation following ALK-TKI resistance in lung adenocarcinoma: a Case Report
in Thoracic Oncology
Frontiers in Oncology
Original Research
Published on 12 Feb 2026
The value of metabolic parameters on dynamic 18F-FDG PET/CT for predicting lymph node metastasis in non-small cell lung cancer
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2026.1752947
- 251 views
Correction
Published on 11 Feb 2026
Correction: TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2026.1804953
- 216 views
Review
Published on 10 Feb 2026
A comprehensive review of clear cell stromal tumor of the lung: integrating clinicopathology and molecular pathogenesis
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2026.1760048
- 297 views
Systematic Review
Accepted on 09 Feb 2026
Genomic Landscape and Subgroup Stratification of Thymic Epithelial Tumors: A Systematic Meta-Analysis of Next-Generation Sequencing Data
in Thoracic Oncology
Frontiers in Oncology
Review
Accepted on 09 Feb 2026
Targeted Therapies in Lung Cancer: Personalizing Treatment Across the Age Spectrum
in Thoracic Oncology
Frontiers in Oncology
- 246 views
Original Research
Published on 09 Feb 2026
Machine learning model for predicting malnutrition risk in lung cancer patients after thoracoscopic resection: a multi-center study
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2026.1727595
- 439 views
Original Research
Accepted on 06 Feb 2026
CD73 expression as a resistance mechanism in advanced EGFR-mutated non-small cell lung cancer (NSCLC)
in Thoracic Oncology
Frontiers in Oncology
Correction
Published on 06 Feb 2026
Correction: Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2026.1783059
- 332 views
Case Report
Published on 06 Feb 2026
Primary pulmonary histiocytic sarcoma with CNS metastasis: a case report and molecular profiling insights
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2026.1636634
- 511 views
Review
Published on 05 Feb 2026
The role of antibody-drug conjugates in the treatment of lung cancer
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2026.1757564
- 934 views
Original Research
Published on 04 Feb 2026
Utility of PPO-FEV1%pred in predicting postoperative pulmonary complications after secondary surgery in patients with multiple primary lung cancers
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2026.1747652
- 396 views
Brief Research Report
Accepted on 03 Feb 2026
Association of endocrine immune-related adverse events with progression-free survival in advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors with or without anlotinib
in Thoracic Oncology
Frontiers in Oncology
Case Report
Accepted on 03 Feb 2026
Malignant Triton Tumor with Thoracic Region as the Initial Presentation: A Case Report
in Thoracic Oncology
Frontiers in Oncology
Original Research
Accepted on 02 Feb 2026
COL11A1 Promotes Lung Adenocarcinoma Progression via PI3K/AKT/mTOR Pathway: Mechanistic Insights and Development of a COL11A1-Related Prognostic Signature
in Thoracic Oncology
Frontiers in Oncology
- 200 views
Correction
Accepted on 02 Feb 2026
Factors Associated with Secondary Thoracotomy for Hemostasis Following lung surgery: A Retrospective Analysis
in Thoracic Oncology
Frontiers in Oncology
Review
Published on 02 Feb 2026
ROS1-positive non-small cell lung cancer: from genomics to treatment decisions
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2026.1739598
- 798 views
Original Research
Published on 02 Feb 2026
BUB1 promotes lung adenocarcinoma progression by regulating STAT3/GPX4-mediated ferroptosis
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2025.1745238
- 534 views
Original Research
Published on 02 Feb 2026
Identification of candidate biomarker MRPL23 and its prognostic potential in non-small cell lung cancer with emphasis on the squamous cell carcinoma subtype
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2026.1663235
- 494 views